A perfused, parallelized blood brain barrier-tumor platform for compound permeation and efficacy investigations

drug concentrations for the BBB. Our results demonstrate that the in vitro BBB significantly limited drug delivery to the tumor, thereby limiting drug efficacy. Furthermore, drug-induced BBB disruption occurred at sub-toxic doses, which led to increased drug permeation to the glioma models. Finally, cell-model-specific responses revealed distinct cytotoxicity behavior, demonstrating the importance of personalized therapy testing. Our scalable BBB-tumor platform provides a physiologically relevant in vitro model system to assess drug permeation, cytotoxicity, and tumor-BBB interactions and offers the potential to advance the discovery of new effective therapeutics against neurological diseases.